Agilon Health Inc is a healthcare company that focuses on transforming the delivery of primary care through its innovative platform designed for value-based care
By partnering with primary care physicians, Agilon enhances their capabilities and support systems, allowing them to improve patient care and outcomes while managing costs more effectively. The company leverages data analytics and technology to enable a seamless integration of services, facilitating better health management for patients and creating a sustainable model for healthcare providers. Through its collaborations, Agilon is dedicated to creating a more efficient healthcare experience that prioritizes wellness and preventive care.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Cardinal Health (NYSE:CAH) and the best and worst performers in the healthcare providers & services industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including Pediatrix Medical Group (NYSE:MD) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare providers & services industry, including The Ensign Group (NASDAQ:ENSG) and its peers.
Looking back on outpatient & specialty care stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including U.S. Physical Therapy (NYSE:USPH) and its peers.
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Healthcare services company Agilon Health (NYSE:AGL) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.2% year on year to $1.52 billion. On the other hand, next quarter’s revenue guidance of $1.5 billion was less impressive, coming in 12% below analysts’ estimates. Its GAAP loss of $0.26 per share was 14.8% below analysts’ consensus estimates.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
